Regen BioPharma, Inc. (RGBP)
OTCMKTS
· Delayed Price · Currency is USD
0.0650
+0.0140 (27.45%)
Jun 5, 2025, 2:01 PM EDT
Regen BioPharma Income Statement
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | 2015 - 2019 |
| Revenue | 0.24 | 0.24 | 0.24 | 0.24 | 0.17 | 0.11 | Upgrade
|
| Revenue Growth (YoY) | 0% | - | 0.44% | 37.57% | 55.63% | - | Upgrade
|
| Gross Profit | 0.24 | 0.24 | 0.24 | 0.24 | 0.17 | 0.11 | Upgrade
|
| Selling, General & Admin | 0.54 | 0.5 | 0.71 | 0.3 | 0.34 | 0.31 | Upgrade
|
| Research & Development | 0.07 | 0.15 | 0.21 | 0.28 | 0.04 | 0.01 | Upgrade
|
| Operating Expenses | 0.61 | 0.65 | 0.92 | 0.58 | 0.37 | 0.32 | Upgrade
|
| Operating Income | -0.37 | -0.42 | -0.69 | -0.34 | -0.2 | -0.21 | Upgrade
|
| Interest Expense | -0.13 | -0.1 | -0.06 | -0.21 | -0.37 | -0.94 | Upgrade
|
| Interest & Investment Income | - | - | - | 0 | 0 | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.43 | -0.14 | 1.9 | 3 | -4.26 | 4.57 | Upgrade
|
| EBT Excluding Unusual Items | -0.93 | -0.66 | 1.16 | 2.45 | -4.83 | 3.41 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.2 | -0.2 | - | 0.03 | -1.16 | - | Upgrade
|
| Legal Settlements | - | - | - | - | -0.8 | - | Upgrade
|
| Other Unusual Items | - | - | 0 | -0.03 | 0.02 | - | Upgrade
|
| Pretax Income | -1.13 | -0.87 | 1.16 | 2.44 | -6.77 | 3.41 | Upgrade
|
| Net Income | -1.13 | -0.87 | 1.16 | 2.44 | -6.77 | 3.41 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | 0.13 | 0.22 | - | - | Upgrade
|
| Net Income to Common | -1.13 | -0.87 | 1.02 | 2.23 | -6.77 | 3.41 | Upgrade
|
| Net Income Growth | - | - | -52.67% | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 15 | 8 | 7 | 6 | 4 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 15 | 8 | 7 | 6 | 4 | 2 | Upgrade
|
| Shares Change (YoY) | 123.69% | 16.21% | 12.79% | 56.19% | 113.61% | -31.93% | Upgrade
|
| EPS (Basic) | -0.08 | -0.11 | 0.14 | 0.36 | -1.68 | 1.82 | Upgrade
|
| EPS (Diluted) | -0.08 | -0.11 | 0.14 | 0.36 | -1.68 | 1.82 | Upgrade
|
| EPS Growth | - | - | -59.25% | - | - | - | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -156.01% | -176.78% | -290.39% | -144.20% | -117.28% | -190.29% | Upgrade
|
| Profit Margin | -479.62% | -366.61% | 432.66% | 945.59% | -3951.79% | 3104.02% | Upgrade
|
| EBIT | -0.37 | -0.42 | -0.69 | -0.34 | -0.2 | -0.21 | Upgrade
|
| EBIT Margin | -156.01% | -176.78% | -290.39% | -144.19% | -117.28% | -190.29% | Upgrade
|
| Revenue as Reported | 0.24 | 0.24 | 0.24 | 0.24 | 0.17 | 0.11 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.